8-K: Monte Rosa's MRT-2359 Shows Strong Prostate Cancer Activity

Monte Rosa Therapeutics announced compelling interim Phase 1/2 clinical data for MRT-2359 in combination with enzalutamide for heavily pretreated metastatic castration-resistant prostate cancer patients with AR mutations.

Summary

• Positive interim data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) was announced.
• The study evaluated 0.5 mg and 0.75 mg of MRT-2359 administered orally on a 21-days-on, 7-days-off schedule in combination with enzalutamide.
• As of the December 3, 2025 data cutoff, 20 patients were enrolled and evaluable for safety, with 14 patients evaluable for RECIST and confirmed non-neuroendocrine mCRPC.
• In the subset of 4 patients confirmed to have AR mutations, a 100% PSA response rate was observed, including 2 patients with PSA90 responses and 2 with PSA50 responses.
• Two RECIST partial responses (1 confirmed, 1 unconfirmed) were seen in the AR mutant subset, resulting in a 100% disease control rate (DCR) in this group.
• An overall DCR of 64% (9 of 14 evaluable patients) was achieved, including 5 patients with wild-type AR or positive for ARV7 transcripts who had stable disease.
• The combination of MRT-2359 and enzalutamide maintained a favorable safety profile, with manageable, primarily mild or moderate (Grade 1 or Grade 2) gastrointestinal adverse events.
• Treatment effects were durable, particularly in patients with AR mutations or those naive to AR inhibitors.
• Clinical activity correlated with MYC and AR pathway activity in baseline biopsies, and modulation of MYC, E2F, and AR pathways was observed in paired tumor biopsies.
• The Phase 1/2 study also included six patients with hormone receptor (HR)+ breast cancer, which demonstrated a favorable safety profile but insufficient evidence of activity to support further development in this population.
• Monte Rosa plans to present updated data from the Phase 1/2 study of MRT-2359 at the ASCO Genitourinary Cancers Symposium in February 2026.
• A new, signal-confirming Phase 2 study of MRT-2359 in combination with a second-generation AR inhibitor for mCRPC patients with AR mutations is anticipated to start in 2026.
• Interim Phase 1 data on MRT-8102, a NEK7-directed MGD for inflammatory diseases, is planned for presentation in early 2026, with dosing initiated in Part 3 of the study to evaluate early proof of concept in subjects at increased CVD risk.

Sentiment

Score: 8

Explanation: The interim clinical data for MRT-2359 in mCRPC patients with AR mutations is highly positive, showing compelling efficacy (100% PSA response, 100% DCR, RECIST partial responses) and a favorable safety profile in a heavily pretreated population. This significantly de-risks the program and supports advancement to a Phase 2 study. The negative outcome in breast cancer is a minor setback for that specific indication but does not overshadow the strong prostate cancer data. The update on MRT-8102 is also positive, indicating progress in another pipeline asset.

Positives

• 100% PSA response rate (4 of 4 patients) in AR-mutant mCRPC patients treated with MRT-2359 in combination with enzalutamide, including 2 PSA90 and 2 PSA50 responses.
• 100% disease control rate (DCR) in the AR-mutant mCRPC patient population.
• Two RECIST partial responses (1 confirmed, 1 unconfirmed) were observed in the AR-mutant subset.
• An overall disease control rate (DCR) of 64% (9 of 14 evaluable patients) was achieved in the mCRPC study.
• The combination of MRT-2359 and enzalutamide demonstrated a favorable safety profile, with manageable, primarily mild or moderate (Grade 1 or Grade 2) gastrointestinal adverse events.
• Treatment effects were durable, particularly in patients with AR mutations or those naive to AR inhibitors.
• Biomarker analysis confirmed that MRT-2359 modulated MYC, E2F, and AR pathways, supporting its mechanism of action.
• Plans to initiate a signal-confirming Phase 2 study for MRT-2359 in mCRPC patients with AR mutations in 2026, with potential for expansion into additional patient subsets and advancement to registrational studies.
• Progress on MRT-8102, with dosing initiated in Part 3 of its Phase 1 study to evaluate early proof of concept in subjects at increased cardiovascular disease (CVD) risk.

Negatives

• The Phase 1/2 study of MRT-2359 in hormone receptor (HR)+ breast cancer patients did not present sufficient evidence of activity to support further development in that population.

Risks

• Forward-looking statements are subject to numerous risks and uncertainties, including the ability to grow the product pipeline and successfully complete research, development, and commercialization of drug candidates.
• There are inherent uncertainties regarding the timing and results of clinical trials and the ability to conduct and complete them.
• Actual results, performance, or achievement could differ materially and adversely from those anticipated or implied in forward-looking statements.
• Reliance on third-party studies, publications, surveys, and other data that have not been independently verified, and for which no representations are made as to adequacy, fairness, accuracy, or completeness.
• No independent source has evaluated the reasonableness or accuracy of internal estimates or research, and reliance should not be made on information based on such estimates.

Future Outlook

Monte Rosa plans to present updated MRT-2359 data at the ASCO Genitourinary Cancers Symposium in February 2026 and initiate a signal-confirming Phase 2 study of MRT-2359 in combination with a second-generation AR inhibitor for mCRPC patients with AR mutations in 2026. This Phase 2 study has the potential to expand into additional patient subsets and position the program for advancement into registrational studies. Interim Phase 1 data for MRT-8102 in inflammatory diseases is expected in early 2026, with dosing already initiated in Part 3 of the study to evaluate early proof of concept.

Management Comments

• "We continue to be highly encouraged by the clinical activity observed with MRT-2359 in combination with enzalutamide in heavily pretreated mCRPC patients, a population with limited therapeutic options, with an overall disease control rate (DCR) of 64%." Markus Warmuth, M.D., Chief Executive Officer.
• "The responses seen in the subset of patients harboring AR mutations were particularly compelling, with 4 of 4 patients demonstrating a PSA response, including 2 PSA90 responses and 2 PSA50 responses. Two of the 4 patients with AR mutations showed a RECIST response, and the DCR in the AR mutant population was 100%." Markus Warmuth, M.D., Chief Executive Officer.
• "We were also pleased to see through our biomarker work that MRT-2359 significantly impacted both the MYC and the E2F signaling pathways, suggesting a mechanism of action that is at least in part independent of inhibiting AR signaling, and confirming our preclinical studies." Markus Warmuth, M.D., Chief Executive Officer.
• "Given these findings and the favorable safety profile observed to date, we believe there is a significant opportunity for MRT-2359 in the rapidly evolving treatment landscape of prostate cancer." Markus Warmuth, M.D., Chief Executive Officer.
• "While the data from the ongoing trial continue to mature, we plan to initiate a new, signal-confirming Phase 2 study, evaluating MRT-2359 in combination with a second-generation AR inhibitor in mCRPC patients with AR mutations." Filip Janku, M.D., Ph.D., Chief Medical Officer.
• "Data from this study have the potential to confirm MRT-2359s clinical activity and may position the program for advancement into registrational studies." Filip Janku, M.D., Ph.D., Chief Medical Officer.

Industry Context

The positive interim data for MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients, particularly those with androgen receptor (AR) mutations, addresses a critical unmet need in a patient population with limited therapeutic options. The drug's mechanism of action, involving the modulation of MYC and E2F pathways, suggests a differentiated approach that could complement or offer an alternative to existing AR inhibitors. This positions Monte Rosa at the forefront of developing novel molecular glue degraders (MGDs), an innovative modality with broad potential in oncology and inflammatory diseases, contributing to the rapidly evolving treatment landscape for prostate cancer.

Comparison to Industry Standards

• The patient characteristics for the MRT-2359 + Enzalutamide study (N=20) were compared to a Mevrometostat + Enzalutamide Phase I trial (N=47), noting that MRT-2359's cohort was heavily pretreated (e.g., 75% previously treated with second-gen AR inhibitor vs. 57% for Mevrometostat; 80% with taxane chemotherapy vs. 49% for Mevrometostat; 55% with Pluvicto vs. not disclosed for Mevrometostat).
• The PSA response rate in the overall population for MRT-2359 + enzalutamide suggests activity at least comparable to data shown in the Phase 1 study of mevrometostat + enzalutamide, though cross-trial comparisons should be interpreted with caution due to differences in trial designs and patient populations.
• The safety profile of MRT-2359 + enzalutamide, characterized by manageable mild or moderate gastrointestinal adverse events, is suggested to be potentially favorable over EZH2 inhibitors, although specific comparative data for EZH2 inhibitors were not provided in the filing.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical data for a key pipeline asset (MRT-2359), potentially increasing company valuation and future revenue prospects.
• Patients (mCRPC with AR mutations): Potential for a new, effective treatment option for a heavily pretreated population with limited alternatives.
• Medical Community: New data contributes to the understanding of molecular glue degraders and their potential in prostate cancer, potentially influencing future treatment paradigms.
• Employees: Positive news could boost morale and confidence in the company's research and development capabilities.

Next Steps

• Present updated data from the Phase 1/2 study of MRT-2359 at the ASCO Genitourinary Cancers Symposium in February 2026.
• Initiate a signal-confirming Phase 2 study of MRT-2359 in combination with a second-generation AR inhibitor in mCRPC patients with AR mutations, anticipated to start in 2026.
• The planned Phase 2 study will evaluate PSA response, RECIST response, duration of response (DoR), progression-free survival (PFS), radiographic progression-free survival (rPFS), and safety.
• The Phase 2 study has the potential to expand into additional patient subsets, including patients naive to 2nd generation AR inhibitors.
• Present interim Phase 1 data on MRT-8102 in early 2026.

Key Dates

Recommendation

The interim Phase 1/2 clinical data for MRT-2359 in metastatic castration-resistant prostate cancer (mCRPC) patients with androgen receptor (AR) mutations is exceptionally strong, demonstrating a 100% PSA response rate and 100% disease control rate, including RECIST partial responses, in a heavily pretreated population. This level of efficacy, combined with a favorable safety profile, significantly de-risks the program and suggests a high probability of success in subsequent clinical stages. The planned initiation of a signal-confirming Phase 2 study in 2026 further solidifies the development path. While the breast cancer indication was discontinued, the primary focus on mCRPC, a large and underserved market, presents a substantial commercial opportunity. The progress with MRT-8102 also adds value to the pipeline. Given these compelling results and the potential for MRT-2359 to become a significant treatment in prostate cancer, a strong buy recommendation is warranted for long-term investors.

Keywords

Monte Rosa Therapeutics, MRT-2359, enzalutamide, metastatic castration-resistant prostate cancer, mCRPC, AR mutations, molecular glue degrader, GSPT1, clinical trial, Phase 1/2, oncology, biotechnology, drug development, PSA response, RECIST response, MRT-8102, inflammatory diseases, NEK7, NLRP3 inflammasome, clinical data, biomarker, MYC pathway, E2F pathway, prostate cancer treatment